“Injective’s EVM L2 Takes Aim at Ethereum, Cosmos, and Solana; AI Crypto Lures Whale Investors, Challenging Injective’s Dominance”


The blockchain industry is constantly evolving, with new projects and developments emerging every day. In this fast-paced space, two projects have caught the attention of investors and developers alike: Injective Labs and InQubeta.

Injective Labs recently launched inEVM, its very own Ethereum Virtual Machine (EVM) Layer 2 roll-up. This innovative solution allows for true interoperability across leading blockchains like Ethereum, Cosmos, and Solana. With its seamless integration of the familiar EVM environment, Injective is positioning itself as a game-changer in the industry.

InQubeta, on the other hand, is taking a different approach with its upcoming crypto ICO platform. This project aims to revolutionize the way AI tech startups raise capital by allowing them to mint their investment opportunities as NFTs. The platform also offers a unique fractional investment model, allowing users to diversify their portfolios by investing in multiple AI startups.

Both Injective and InQubeta have already gained significant traction in their respective spaces. Injective has established itself as one of the fastest-growing Layer-1 blockchains, while InQubeta’s presale has already raised over $11.6 million in funding.

With its interoperability and EVM compatibility, Injective is making blockchain development smoother and faster. Meanwhile, InQubeta is pioneering a new way for AI startups to raise capital with its innovative NFT-based fundraising model.

To stay updated on these exciting developments, visit InQubeta’s website and join their thriving community on Twitter. These projects are definitely worth keeping an eye on in the fast-paced world of blockchain.

Related articles

Recent articles